386 related articles for article (PubMed ID: 14523602)
1. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
[TBL] [Abstract][Full Text] [Related]
2. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
[TBL] [Abstract][Full Text] [Related]
3. Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification.
Al-Fakhri N; Hofbauer LC; Preissner KT; Franke FE; Schoppet M
Thromb Haemost; 2005 Dec; 94(6):1335-7. PubMed ID: 16411417
[No Abstract] [Full Text] [Related]
4. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
[TBL] [Abstract][Full Text] [Related]
5. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
6. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
7. The OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer LC; Kühne CA; Viereck V
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):268-75. PubMed ID: 15615494
[TBL] [Abstract][Full Text] [Related]
8. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE
J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731
[TBL] [Abstract][Full Text] [Related]
9. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
10. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
11. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
12. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
13. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
Mochizuki S; Kiyokawa A; Nagayama Y
Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
[TBL] [Abstract][Full Text] [Related]
14. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.
Ritchlin CT; Schwarz EM; O'Keefe RJ; Looney RJ
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):276-84. PubMed ID: 15615495
[TBL] [Abstract][Full Text] [Related]
15. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
16. [Clinical implications of new insights into the regulation of bone resorption].
Lems WF; Bijlsma JW
Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
[TBL] [Abstract][Full Text] [Related]
17. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
Sandberg WJ; Yndestad A; Øie E; Smith C; Ueland T; Ovchinnikova O; Robertson AK; Müller F; Semb AG; Scholz H; Andreassen AK; Gullestad L; Damås JK; Frøland SS; Hansson GK; Halvorsen B; Aukrust P
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):857-63. PubMed ID: 16424351
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
[TBL] [Abstract][Full Text] [Related]
20. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].
Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M
Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
